Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Muñiz, I. Herráez, E. Bollo, S. Fernández, B. Cartón, E. Santalla, F. Diez (León, Spain). Combined pulmonary fibrosis and emphysema syndrome (CFPE). Eur Respir J 2012; 40: Suppl. 56, 715

Member's Comments

No comment yet.

Related content which might interest you: Combined fibrosis and emphysema syndrome Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Combined fibrosis and emphysema syndrome Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Combined fibrosis and emphysema syndrome Source: ERS Courses: Interstitial Lung Diseases Year: 2019 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Combined pulmonary fibrosis and emphysema syndrome, DIP and RB-ILD Source: ERS Course 2016 Year: 2016 Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema Source: ERJ Open Res, 7 (3) 00316-2021; 10.1183/23120541.00316-2021 Year: 2021 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Comorbidities in patients with the combined pulmonary fibrosis and emphysema syndrome (CPFE) Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Source: Eur Respir J 2010; 35: 105-111 Year: 2010 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012